Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia

British Journal of Haematology

Volumn 113, Issue 4, 2001, Pages 975-982

  Braess, Jan ^a   Jahns Streubel, Gerlinde ^b   Schoch, Claudia ^a   Haase, Detlef ^c   Haferlach, Torsten ^a   Fiegl, Michael ^a   Voss, Stefanie ^c   Kern, Wolfgang ^a   Schleyer, Eberhardt ^d   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

AML; Cytogenetics; Cytokines; Cytosine arabinoside; Proliferation

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; KARYOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CYTARABINE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; INVERSION, CHROMOSOME; KARYOTYPING; LEUKEMIA, MYELOID; MIDDLE AGED; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 0034937432     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02866.x     Document Type: Article

References (44)

1. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects
2. The clinical significance of karyotype in acute myelogenous leukemia
3. Interleukin-6 production by the blast cells of acute myeloblastic leukemia: Regulation by endogenous interleukin-1 and biological implications
4. RAS and leukemia: From basic mechanisms to gene-directed therapy
5. Fourth International Workshop on chromosomes in leukemia 1982: Abnormalities of chromosome 7 resulting in monosomy 7 or in deletion of the long arm (7q-): Review of translocations, breakpoints, and associated abnormalities
6. The treatment of adult acute myeloid leukemia
7. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
8. The pharmacodynamic basis for the increased anti-leukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high endogenous proliferation rate
9. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
10. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells
11. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation
12. In vitro growth in acute myeloblastic leukaemia: Relationship with other clinico-biological characteristics of the disease
13. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
14. Acute myeloid leukemia in the elderly: A critical review of therapeutic approaches and appraisal of results of therapy
15. Cell-cycle, protein content, and nuclear size in acute myeloid leukemia
16. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines
17. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside
18. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia
19. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia
20. Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia
21. Prognostic factors in elderly patients with acute myeloid leukaemia
22. An in vitro model to predict clinical response in adult acute myelogenous leukemia
23. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
24. Prognosticheskoe znachenie parametrov proliferatsii blastnykh kletok kostnogo mozga u bol'nykh ostrym leikozom
25. Correlation of cytotoxicity with incorporation of ara-C into DNA
26. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function
27. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del (5q)
28. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia
29. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia
30. Clinical significance of cytogenetics in acute myeloid leukemia
31. The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia
32. Adult acute non-lymphoblastic leukaemia: Reliability and prognostic significance of pretreatment bone marrow S-phase size determined by flow cytofluorometry
33. 1-Beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of vivo murine tumor cell response
34. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8 (ETO)-specific antisense oligonucleotide
35. Parental origins of chromosome 7 loss in childhood monosomy 7 syndrome
36. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia
37. Complex chromosome aberrations in patients with de novo AML show a poor prognosis despite intensive treatment: A study of 90 patients
38. Persistent Epstein-Bart virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders
39. Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia
40. Fourth International Workshop on chromosomes in leukemia 1982: Deletion of 5q
41. Prognostic value of S-phase cells in AML patients
42. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
43. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map
44. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group